Metraipolis › archive › dc_a5a08092e1d7

Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast… — Europe PMC PMID:40922517

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40922517
DOI
10.1080/07853890.2025.2557509
License (as archived)
solo-consultazione
Archived
2026-11-10T02:16:25.942Z
SHA-256 of the archived text
af261f8513b1645d76dbb02babc31898e6627f439f4c76c02c74d19b8e5ace5c
Stable URL of this page
https://metraipolis.com/documento/dc_a5a08092e1d7

How to cite

Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast… — Europe PMC PMID:40922517 — Europe PMC (en), https://europepmc.org/article/MED/40922517 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a5a08092e1d7 (Metraipolis archive dc_a5a08092e1d7, sha256 af261f8513b1645d76dbb02babc31898e6627f439f4c76c02c74d19b8e5ace5c)
BibTeX
@misc{dca5a08092e1d7,
  title = {Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast… — Europe PMC PMID:40922517},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40922517},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a5a08092e1d7; sha256 af261f8513b1645d76dbb02babc31898e6627f439f4c76c02c74d19b8e5ace5c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40922517. Agents can read the archived copy with the MCP tool read_document.